TPA-UK Corrections to Recent British Thyroid Association Comments Regarding Armour Thyroid
On 28 August 2007, TPA-UK sent a response to Professor Weetman (President)
and Dr. Abraham (Secretary) to the BTA. Our aim is to secure an appropriate
amendment to the above BTA Executive Committee Statement on Armour Thyroid
and we look forward to receiving confirmation that this will be carried
out in the very near future. Please print this off and take it to your
GP/Endocrinologist if they refuse to give you a trial of Armour Thyroid
because of the BTA's Executive Committee's misleading and incorrect statement.
We at Thyroid Patient Advocacy (TPA-UK) are frankly appalled that the
BTA are advocating the broadening of the TSH range for use in the initial
diagnosis and subsequent treatment of sub clinical and overt hypothyroidism
when recent research is suggesting quite the opposite. 
Guidelines
usually proclaim the value of “evidence-based medicine” wherein
clinical evidence – for example if the patient says he/she is not
feeling well – is somehow less weighty than evidence based on laboratory
findings. Here, Dr Skinner responds to the BTA in this fact-filled letter.
TPA-UK writes to NHS endocrinologist and general practitioners. The American
Academy of Clinical Endocrinologists (AACE), the nation's largest organisation
of thyroid specialists, has taken the opposite view and confirmed that
hypothyroidism, like many other illnesses that affect predominantly women,
has been vastly under diagnosed. So why has the BTA have recommended doubling
the upper level of the TSH test to 10mU/L?